Progen Co., Ltd. (XKON:296160)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,850.00
-80.00 (-1.01%)
At close: Aug 1, 2025
-1.01%
Market Cap112.18B
Revenue (ttm)450.00M
Net Income (ttm)-15.25B
Shares Out14.29M
EPS (ttm)-3,307.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,670
Average Volume27,676
Open7,930.00
Previous Close7,930.00
Day's Range7,800.00 - 8,050.00
52-Week Range4,515.00 - 9,970.00
Betan/a
RSI49.71
Earnings Daten/a

About Beacon Roofing Supply

Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities. The company’s NTIG platform technology is used for the development of anti-cancer and immune disease treatments. It develops PG-102 for the treatment of obesity with T2DM to control blood sugar, improve metabolic function, and reduce weight in the gastrointestinal tract and adipocytes. The company was founded in 1998 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 296160
Full Company Profile

Financial Performance

In 2022, Progen's revenue was 450.00 million, a decrease of -67.36% compared to the previous year's 1.38 billion. Losses were -15.25 billion, 135.0% more than in 2021.

Financial Statements

News

There is no news available yet.